John A. Kosteva

1.0k total citations · 1 hit paper
12 papers, 496 citations indexed

About

John A. Kosteva is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, John A. Kosteva has authored 12 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in John A. Kosteva's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). John A. Kosteva is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). John A. Kosteva collaborates with scholars based in United States. John A. Kosteva's co-authors include Corey J. Langer, Stephen Bagley, Tracey L. Evans, Charu Aggarwal, Roger B. Cohen, Peter Gabriel, Jeffrey C. Thompson, Evan Alley, Faith Mutale and Christine Ciunci and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology and Lung Cancer.

In The Last Decade

John A. Kosteva

11 papers receiving 493 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

2017 387 citations Stephen Bagley, Shawn Kothari et al. Lung Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John A. Kosteva United States	6	435	204	77	52	48	12	496
Virginia Palomar Coloma France	4	421 1.0×	190 0.9×	118 1.5×	48 0.9×	65 1.4×	5	481
Munehiro Ito Japan	8	481 1.1×	317 1.6×	81 1.1×	31 0.6×	54 1.1×	14	541
Jeffrey M. Lemons United States	5	408 0.9×	211 1.0×	157 2.0×	45 0.9×	79 1.6×	8	523
Guoqiang Wang China	9	455 1.0×	227 1.1×	101 1.3×	88 1.7×	62 1.3×	24	561
Audrey Simonaggio France	10	445 1.0×	278 1.4×	82 1.1×	51 1.0×	48 1.0×	23	567
Matías Chacón Argentina	13	192 0.4×	191 0.9×	71 0.9×	67 1.3×	100 2.1×	56	429
Paloma Martín-Martorell Spain	11	279 0.6×	190 0.9×	35 0.5×	52 1.0×	37 0.8×	30	426
A. Patel United States	5	445 1.0×	154 0.8×	267 3.5×	40 0.8×	31 0.6×	12	542
Lucía Teijeira Spain	10	400 0.9×	100 0.5×	211 2.7×	45 0.9×	28 0.6×	18	485
Kyoji Tsurumi Japan	6	492 1.1×	232 1.1×	103 1.3×	14 0.3×	43 0.9×	11	531

Countries citing papers authored by John A. Kosteva

Since Specialization

Citations

This map shows the geographic impact of John A. Kosteva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Kosteva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Kosteva more than expected).

Fields of papers citing papers by John A. Kosteva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Kosteva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Kosteva. The network helps show where John A. Kosteva may publish in the future.

Co-authorship network of co-authors of John A. Kosteva

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Kosteva. A scholar is included among the top collaborators of John A. Kosteva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Kosteva. John A. Kosteva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Barsouk, Adam, Jonathan Sussman, Benjamin Aaron Bleiberg, et al.. (2025). Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clinical and Research Reports. 6(9). 100851–100851.

Barsouk, Adam, Margaret Stalker, Jonathan Sussman, et al.. (2024). Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy. Clinical Lung Cancer. 26(2). 158–163.e2. 2 indexed citations

Aggarwal, Charu, Melina E. Marmarelis, Wei‐Ting Hwang, et al.. (2023). Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. JCO Precision Oncology. 7(7). e2300191–e2300191. 22 indexed citations

Barsouk, Adam, Abigail Doucette, Roger B. Cohen, et al.. (2023). Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation. Clinical Lung Cancer. 25(3). e161–e171. 2 indexed citations

Aggarwal, Charų C., Erica L. Carpenter, Wei‐Ting Hwang, et al.. (2022). Improving comprehensive genotyping in patients with newly diagnosed non-squamous NSCLC: Results from a prospective trial of a behavioral nudge intervention.. Journal of Clinical Oncology. 40(28_suppl). 362–362. 1 indexed citations

Aggarwal, Charu, Melina E. Marmarelis, Wei‐Ting Hwang, et al.. (2022). Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). 9022–9022. 13 indexed citations

Kothari, Shawn, Stephen Bagley, Charu Aggarwal, et al.. (2017). P3.02c-029 Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab. Journal of Thoracic Oncology. 12(1). S1290–S1290. 9 indexed citations

Bagley, Stephen, Shawn Kothari, Charu Aggarwal, et al.. (2017). P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1289–S1289. 4 indexed citations

Bagley, Stephen, Shawn Kothari, Charu Aggarwal, et al.. (2017). Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 106. 1–7. 387 indexed citations breakdown →

10.

Bagley, Stephen, Shawn Kothari, Charu Aggarwal, et al.. (2017). P3.02c-069 Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1318–S1318. 2 indexed citations

11.

Bagley, Stephen, John A. Kosteva, Tracey L. Evans, & Corey J. Langer. (2016). Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. 6. 20–23. 26 indexed citations

12.

Kosteva, John A. & Corey J. Langer. (2008). The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Current Opinion in Oncology. 20(2). 155–161. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact